Doctor training could be key to better diabetes control

NCT ID NCT05715307

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study investigates whether giving endocrinologists (diabetes specialists) a one-week intensive training program helps them manage type 2 diabetes more effectively. The training includes a hospital stay experience and hands-on patient management. Researchers will compare blood sugar control in patients treated by trained versus untrained doctors to see if the program makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intensive experiential training for endocrinologists
What this could lead to
If successful, this approach could improve diabetes management by training doctors more effectively, leading to better patient outcomes.
What could go wrong
The trial is relatively small and focuses on a specific training method; results may not apply broadly or show significant improvement over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2,017 people

The number who actually took part.

Started

Feb 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Subjects with type 2 diabetes mellitus; * 2\. First visit to MMC; * 3\. Age 40-65 years; * 4\. 24.0 \< BMI ≤ 35.0 kg/m2; * 5\. Subjects with screening HbA1c ≥ 7.5% and ≤ 10.0%, and the fasting blood glucose ≥ 8.0 mmol/l and \< 13.3 mmol/l; * 6\. Duration of diabetes less than 10 years; * 7\. Subjects with poorly controlled blood glucose only by 1-2 kinds of non-insulin hypoglycemic drugs for at least 2 months; * 8\. Subjects understand the nature, significance, potential benefits, inconvenience, and risks of the study before it starts, and fully understand the study procedures and voluntarily sign the informed consent form. Exclusion Criteria: * 1\. Subjects with type 1 diabetes, single gene mutation diabetes, diabetes due to pancreatic injury or other secondary diabetes (such as Cushing's syndrome, thyroid dysfunction or acromegaly, etc.); * 2\. Subjects with serious cardiovascular diseases, such as congenital heart disease, rheumatic heart disease, hypertrophic or dilated cardiomyopathy and chronic congestive heart failure (NYHA III-IV); acute myocarditis within 12 months; severe liver and kidney dysfunction (eGFR\<60mL/min/1.73m2); mental disorder, etc. * 3\. Subjects with acute diabetic complications in the past 3 months; * 4\. Subjects who were or are using insulin to control diabetes in the past 3 months; * 5\. History of drug abuse; * 6\. History of sexually transmitted disease (such as syphilis, and HIV infection \[AIDS\], etc.) or in the active phase of infectious disease (such as viral hepatitis, and tuberculosis, etc.); * 7\. Subjects who are pregnant or in lactation; * 8\. Participation in other clinical trials; * 9\. Any condition that in the judgement of the investigator precludes participation. Details please see the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.